Correlation Engine 2.0
Clear Search sequence regions


  • drug combinations (2)
  • food (1)
  • free (5)
  • glaucoma (2)
  • humans (1)
  • patients (1)
  • thiophenes (2)
  • timolol (15)
  • Sizes of these terms reflect their relevance to your search.

    The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence and clinical experience. The indications and role of DTFC in current glaucoma management are critically discussed. Preserved DTFC became the first intraocular pressure (IOP)-lowering fixed combination (FC) approved by the US Food and Drug Administration (FDA) and remains one of most commonly used medications worldwide. The pharmacological properties of DTFC reflect those of its two time-tested constituents, i.e., the carbonic anhydrase inhibitor dorzolamide and the non-selective beta-blocker timolol. In regulatory studies DTFC lowers IOP on average by 9 mmHg (32.7%) at peak and by 7.7 mmHg (27%) at trough. In trials DTFC shows equivalence to unfixed concomitant therapy, but in real-life practice it may prove superior owing to enhanced convenience, elimination of the washout effect from the second drop, improved tolerability, and better adherence. PF DTFC became the first PF FC approved, first in unit-dose pipettes, and more recently in a multidose format. Cumulative evidence has confirmed that PF DTFC is at least equivalent in efficacy to preserved DTFC and provides a tangible clinical benefit to patients with glaucoma suffering from ocular surface disease by improving tolerability and adherence. Finally, we identify areas that warrant further investigation with preserved and PF DTFC.

    Citation

    Anastasios G Konstas, Leopold Schmetterer, Andreas Katsanos, Cindy M L Hutnik, Gábor Holló, Luciano Quaranta, Miguel A Teus, Hannu Uusitalo, Norbert Pfeiffer, L Jay Katz. Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future. Advances in therapy. 2021 Jan;38(1):24-51

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33108623

    View Full Text